Core Viewpoint - China Resources Pharmaceutical (03320) has successfully issued the first phase of its 2025 medium-term notes, raising a total of RMB 3 billion with a maturity of three years and an annual interest rate of 2.19 [1] Group 1 - The first phase of the 2025 medium-term notes was completed on December 15, 2025 [1] - The funds raised from this issuance will be used to repay interest-bearing debts of China Resources Pharmaceutical Commercial or its subsidiaries [1]

证券日报网讯 12月15日晚间，国药一致发布公告称，公司第十届董事会2025年第九次临时会议审议通 过《关于其他应收款坏账损失核销的议案》《关于召开2025年第三次临时股东会的议案》。 （文章来源：证券日报） ...

证券日报网讯12月15日晚间，国药一致（000028）发布公告称，公司将于2025年12月31日召开2025年第 三次临时股东会。本次股东会将审议《关于2025年度董事薪酬(津贴)的方案》。 ...

资金流向方面，今日该股主力资金净流入3.00亿元，其中，特大单净流入3.38亿元，大单资金净流出 3800.20万元。近5日主力资金净流入2.49亿元。 融资融券数据显示，该股最新（12月12日）两融余额为3.30亿元，其中，融资余额为3.29亿元，融券余 额为110.26万元。近5日融资余额合计增加4872.00万元，增幅为17.37%，融券余额合计增加64.99万元， 增幅143.59%。（数据宝） 重药控股12月15日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 浙商证券股份有限公司杭州五星路证券营业部 | 10311.43 | 0.25 | | 买二 | 国泰海通证券股份有限公司上海长宁区江苏路证券营业 部 | 5018.39 | 25.65 | | 买三 | 深股通专用 | 4977.07 | 4661.00 | | 买四 | 国泰海通证券股份有限公司南京太平南路证券营业部 | 3144.39 | 1225.17 | | 买五 | 国金证券股份有限公司上海静安区 ...

证券之星消息，12月15日医药商业板块较上一交易日上涨0.38%，重药控股领涨。当日上证指数报收于 3867.92，下跌0.55%。深证成指报收于13112.09，下跌1.1%。医药商业板块个股涨跌见下表： 从资金流向上来看，当日医药商业板块主力资金净流入8733.26万元，游资资金净流出9395.76万元，散 户资金净流入662.51万元。医药商业板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 ...

| 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2025.12.12 | -4.34 | 14.10 | -25914.79 | | 2025.12.11 | 10.07 | 1.81 | 7790.60 | | 2025.12.10 | 9.94 | 2.96 | 13250.54 | | 2025.12.09 | -1.66 | 1.07 | -239.76 | | 2025.12.08 | -0.73 | 1.17 | -11.11 | | 2025.12.05 | -0.18 | 1.13 | -849.05 | | 2025.12.04 | 0.18 | 1.49 | -519.93 | | 2025.12.03 | 1.30 | 2.18 | -1331.55 | | 2025.12.02 | 1.89 | 1.72 | 173.93 | | 2025.12.01 | 0.38 | 0.84 | -226.57 | （文章来源：证券时报网） 龙虎榜数据显示，该股因连续三个交易日内，涨幅偏离值累计达20%上榜龙 ...

Investment Rating - The report maintains a "Neutral" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The 2025 National Basic Medical Insurance Drug List has been published, adding 114 new drugs, with a negotiation/competitive bidding success rate of 88%, higher than the 76% in 2024. The total number of drugs in the insurance list has increased to 3,253, including 1,857 Western medicines and 1,396 traditional Chinese medicines [12]. - The pharmaceutical sector has underperformed compared to the CSI 300 index, with a year-to-date return of 14.65% against the CSI 300's 16.43%, resulting in a 1.77 percentage point lag [21]. - The current valuation of the pharmaceutical sector is 33.0 times PE based on 2026 earnings forecasts, representing a 41% premium over the overall A-share market (excluding financials) [21]. Summary by Sections Recent Performance - The pharmaceutical and biotechnology sector has seen a decline of 1.04% in the past week, ranking 17th among 31 primary sub-industries. The sub-sectors of chemical pharmaceuticals, biological products, medical devices, pharmaceutical commerce, traditional Chinese medicine, and medical services have experienced weekly changes of -0.75%, -1.85%, -1.79%, -4.26%, -2.03%, and +1.67%, respectively [11][22]. Market Dynamics - The pharmaceutical sector's performance from the beginning of 2025 to December 12 shows a return of 14.65%, while the CSI 300 index returned 16.43%, indicating a relative underperformance of 1.77 percentage points [21]. Valuation Analysis - The current valuation of the pharmaceutical sector is 29.0 times PE based on trailing twelve months (TTM) earnings, which is below the historical average of 35.0 times PE from January 4, 2010, to December 12, 2025. The sector's premium over the overall A-share market (excluding financials) is 16.3% [21]. Industry Developments - The first commercial health insurance drug list has been established, including 19 drugs that enjoy various policy benefits. This list is effective from January 1, 2026, to December 31, 2027, and includes five CAR-T products [12].

（原标题：上海医药现2笔大宗交易 合计成交28.10万股） | 成交量 | 成交金 额 | 成交价 | 相对当日 收盘折溢 | 买方营业 | | | --- | --- | --- | --- | --- | --- | | （万 | | 格 | | | 卖方营业部 | | 股） | （万 | （元） | 价 | 部 | | | | 元） | | （%） | | | | 15.59 12.51 | 281.46 225.75 | 18.05 18.05 | 0.00 0.00 | 机构专用 机构专用 | 瑞银证券有限责任公司上海花园石桥路证券营业 部 瑞银证券有限责任公司上海花园石桥路证券营业 部 | 上海医药12月12日大宗交易平台共发生2笔成交，合计成交量28.10万股，成交金额507.21万元。成交价 格均为18.05元。从参与大宗交易营业部来看，机构专用席位共出现在2笔成交的买方或卖方营业部中， 合计成交金额为507.21万元，净买入507.21万元。 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 证券时报•数据宝统计显示，上海医药今日收盘价为18.05元，上涨1.35%，日换手率为1 ...

Group 1 - *ST Hu Ke received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation for suspected violations of information disclosure laws, leading to a formal case being opened against the company [2] - The company stated that its production and operational activities are currently normal and that the investigation will not have a significant impact on its management and operations [4] - The main business of *ST Hu Ke involves the trade of agricultural and chemical products, classified under "F51 Wholesale Industry" according to the CSRC [4] Group 2 - As of December 12, *ST Hu Ke's stock price was 3.81 yuan per share, with a total market capitalization of 1.253 billion yuan [5] - Humanwell Healthcare announced that it received an administrative penalty notice from the CSRC for failing to disclose non-operating fund occupation and related transactions in its annual reports, which contained significant omissions and false records [5] - Humanwell Healthcare's stock will be subject to risk warnings starting December 16, with a daily price fluctuation limit of 5% after being placed on the risk warning board [6] Group 3 - Humanwell Healthcare, established in 1993, is a leading pharmaceutical company in Hubei Province, with a strong presence in various therapeutic areas and a comprehensive pharmaceutical value chain [8] - As of December 12, Humanwell Healthcare's stock price was 18.15 yuan per share, with a total market capitalization of 29.625 billion yuan [9]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医药商业板块主力资金净流出3.56亿元，游资资金净流出3613.06万元，散户资 金净流入3.92亿元。医药商业板块个股资金流向见下表： 证券之星消息，12月12日医药商业板块较上一交易日下跌0.97%，海王生物领跌。当日上证指数报收于 3889.35，上涨0.41%。深证成指报收于13258.33，上涨0.84%。医药商业板块个股涨跌见下表： ...